Pfizer's crizotinib superior to chemotherapy in improving PFS in ALK-positive NSCLC
This article was originally published in Scrip
Executive Summary
Pfizer has reported Phase III trial data showing that its anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib) is superior to standard chemotherapy in improving progression-free survival (PFS) in patients with previously-treated ALK-positive advanced non-small cell lung cancer (NSCLC).